Tangent Medical an innovator of IV therapy products, announced it has received CE Mark approval for the NovaCath Integrated IV Catheter System. The approval demonstrates that NovaCath meets the safety, health and environmental requirements in the European Union and clears the company to introduce NovaCath throughout Europe and other countries recognizing the CE Mark.
“This is another significant milestone for Tangent Medical and an important achievement as it allows us to begin selling NovaCath in Europe,” said Tangent Medical President Eric Sandberg. “NovaCath is a breakthrough technology designed to address IV therapy challenges common throughout the world. Receiving CE Mark approval gives us the opportunity to advance the safety and efficacy of IV therapy for patients, clinicians, and hospitals in additional international markets.”
“NovaCath uniquely integrates several patented design elements that not only reduce the risk of IV complications but also improve healthcare worker safety and clinical efficiency,” said Curtis Bloch, Vice President of Sales & Marketing for Tangent Medical. “Our innovative, award- winning design delivers advanced catheter stabilization, next-generation tubing management, passive needle encapsulation and blood control on every short-peripheral IV start. Feedback from clinicians has been exceptional. We look forward to introducing NovaCath in Europe.